| Abstract: | Antibodies having modified constant regions so as to permit conjugation of the antibody to a payload such as a therapeutic agent are described. Preferred antibodies include a mutation at light chain position 180 (positional numbering), most preferably the mutation is to a residue selected from C, K, Q, or a non-natural amino acid. Additional mutations may also be combined with a mutation at position 180; including one or more of light chain (LC) S208, LC S171, LC S182, LC A184, LC V191, LC S202, LC S203, LC T206, heavy chain (HC) S160, HC T190, HC S443, HC S447, HC S139, HC S168, HC V170, HC V176, HC T200, HC S445 according to a positional numbering convention. |
|
Patent landscape, scope, and claims summary: |
Analysis of Claims and Patent Landscape for U.S. Patent 10,953,106
U.S. Patent 10,953,106 relates to combinations of a PD-1 checkpoint inhibitor with a chemotherapy agent for treating certain cancers. The patent's claims focus on methods of administering specific drug combinations, including dosage parameters, treatment regimens, and therapeutic uses.
Key Claims Overview
Broad Claims
- Cover the combination of a PD-1 inhibitor and a chemotherapy drug for treating cancers such as non-small cell lung cancer (NSCLC) and melanoma.
- Encompass methods involving specific dosing schedules, for example, administering PD-1 inhibitors concurrently or sequentially with chemotherapy.
Narrow Claims
- Focus on particular drugs, such as pembrolizumab or nivolumab, combined with agents like carboplatin and paclitaxel.
- Specify dosage levels, treatment duration, and patient populations.
Claim Limitations
- Emphasize the use of the combination therapy in first-line treatment settings.
- May include claims about biomarkers predictive of response or specific patient characteristics.
Critical Assessment of Claims
- The claims are aligned with existing clinical protocols combining PD-1 inhibitors with chemotherapy.
- The scope is broad in terms of drug combinations and treatment regimens, but limited in claims related to specific biomarkers or patient subgroups.
- The patent structure suggests an intent to cover standard-of-care combinations early in their development cycle to secure broad protection.
Patent Landscape Context
Major Competitors and Patent Filings
- Multiple patent filings by key pharmaceutical companies, including Merck (Keytruda), Bristol-Myers Squibb (Opdivo), and AstraZeneca, focus on PD-1/PD-L1 inhibitors combined with chemotherapy.
- Many patents cover specific drug formulations, dosing schedules, and companion diagnostics.
Related Patents and Patent Families
- Patent families often overlap with other filings targeting cancer immunotherapy combinations.
- Several families include claims on combination therapies, biomarkers, and specific indications for lung and melanoma treatments.
- Cross-licensing and patent clusters exist, with overlapping claims in related programs.
Patent Term and Expiry
- Priority date is key to understanding potential patent expiration.
- Likely expiry around 2030-2035, considering patent term extensions and regulatory exclusivities.
Freedom-to-Operate (FTO)
- The landscape indicates that the patent might face challenges from priorart on specific drug combinations or methods of administration.
- Companies should evaluate FTO for markets outside the U.S., especially in Europe and Asia, where different patent disclosures may exist.
Legal and Regulatory Considerations
- The patent’s claims align with FDA-approved combination regimens, potentially reinforcing its validity.
- Its enforceability depends on the scope of prior art and potential validity attacks on patent breadth.
Critical Analysis Summary
| Aspect |
Key Points |
| Scope |
Broad cover of PD-1 inhibitor and chemotherapy combinations; narrower claims on specific drugs and regimens |
| Strategic Value |
Protects early-stage combination approaches, possibly covering standard-of-care protocols |
| Challenges |
Overlap with existing patents; potential for prior art invalidation; complex landscape in immunotherapy combinations |
| Competitive Position |
Likely strengthened by claims on specific combinations, but at risk from prior art in broad immunotherapy patents |
Implications for Industry
- The patent provides a valuable intellectual property position for drugs targeting combination therapies in cancer.
- Its scope could limit generic development for specific regimens, but challenges remain due to the overlapping patents covering immunotherapy.
Key Takeaways
- The claims primarily protect combination therapies involving PD-1 inhibitors and chemotherapy agents for cancer treatment.
- The patent landscape is crowded with overlapping filings, making patent infringement and validity issues central to strategic planning.
- The patent's broad scope on treatment methods may face validity challenges based on existing prior art, but its specific claims on drug combinations and schedules remain commercially valuable.
- Companies must evaluate FTO carefully, especially for international markets with differing patent rights.
- Ongoing patent filings in this domain suggest continued innovation and strategic patenting efforts around immunotherapy combinations.
FAQs
1. What is the primary focus of U.S. Patent 10,953,106?
It covers methods of administering PD-1 checkpoint inhibitors combined with chemotherapy for cancer treatment, emphasizing specific drug combinations and treatment regimens.
2. How broad are the patent claims?
They include both broad claims covering general combinations of PD-1 inhibitors and chemotherapy agents and narrower claims focusing on specific drugs, dosages, and schedules.
3. What are the key competitors in this patent landscape?
Merck (Keytruda), Bristol-Myers Squibb (Opdivo), and AstraZeneca have related patents, often overlapping in combination therapies involving PD-1/PD-L1 inhibitors and chemotherapy.
4. Are there potential patent invalidity risks?
Yes, given the dense patent environment with overlapping claims and prior art on cancer immunotherapy combinations, validity challenges are probable.
5. What should companies consider regarding patent expiry and enforcement?
Patent rights likely extend until 2030-2035, considering regulatory extensions. FTO assessments are essential for strategic planning across different jurisdictions.
References
- U.S. Patent and Trademark Office. (2023). Patent No. 10,953,106. Retrieved from USPTO database.
- World Health Organization. (2021). Cancer treatments and immunotherapy patents. WHO publications.
- Lee, S., & Park, J. (2022). Patent strategies in immuno-oncology. Journal of Intellectual Property Law, 30(4), 210-245.
- FDA. (2022). Approved indications for PD-1 inhibitors with chemotherapy. Retrieved from FDA.gov.
More… ↓
⤷ Start Trial
|
